“The premise here is simple: biotech investing is just as it was before COVID-19 and as it will be when the pandemic is finally over,” begins the author of today’s article. If one accepts this premise, what does that mean for investing in the three fronts of the war on the coronavirus (testing, treatment and vaccination)? For the author’s overview…
The biotech firm highlighted in today’s article, which in the past year has refocused its efforts on a newer cancer-fighting technology, is the No. 4 best-performing stock on the Nasdaq Composite Index and the No. 1 best-performing stock on Canada’s S&P/TSX Composite Index – and despite having already experienced a 3,600% surge, the author notes that “every analyst covering the…
There’s perhaps no greater catalyst for shares of a biotech company than FDA approval of one of its product candidates. Conversely, an unfavorable ruling by the FDA can send shares of a biotech firm plummeting. With the FDA having approved 40 novel drugs so far this year (compared to 27 by this same time last year), today’s article takes a…
The portfolio manager of one biotech-focused hedge fund recently invested a total of $60 million in three biotech stocks – and given his strong performance record and ability to beat the wider biotech sector with his picks, it may be worth taking a look at his selections. For the three biotech stocks in question, CLICK HERE.
While the author of today’s article acknowledges that “biotech investors…tend not to be a squeamish bunch”, he observes that the “looming presidential election could still cause them some visceral discomfort.” Recalling the 2016 presidential campaign, in which both major candidates’ rhetoric regarding drug pricing caused biotech stocks to plummet, he advises that “investors shouldn’t dismiss the possibility of another election-related…
What’s behind biotech’s recent underperformance? One important factor may be the impending presidential election – and as one exchange-traded fund strategist cited in today’s article explains, “…if history repeats, this pullback may represent an attractive buying opportunity.” What does the history of biotech’s performance leading up to and following presidential elections suggest about buying the biotech dip? CLICK HERE.
When it comes to the advantage that emerging coronavirus stocks have over their more established counterparts, the author of today’s article notes that, “While coronavirus vaccine companies such as Moderna, AstraZeneca, and Pfizer have market caps amounting to tens of billions of dollars, small- to mid-cap coronavirus stocks can potentially be multi-baggers, albeit with higher risks.” He proceeds to take…
“With all of the hype about the race to develop coronavirus vaccines, it’s not surprising that short-sellers have piled on some of the stocks of biotechs with COVID-19 vaccine candidates,” acknowledges the author of today’s article. He further points out, however, that “if these companies have good news, there could be a short-squeeze scenario where the stocks skyrocket as short-sellers…
In the wake of two seemingly negative events, shares of the nonalcoholic steatohepatitis (NASH) drug developer focused on in today’s article experienced a sharp sell-off at the end of last week, but one analyst is imploring investors to “view last week’s weakness as a prime buying opportunity” – and sees massive upside potential of 210%. For more on this stock…
Today’s article highlights three biotech penny stocks to watch right now, including one that the author notes has “had an epic year so far”: It started the year trading under $1 and proceeded to go as high as $5.55 before recently being driven down to as low as $1.68 – and may now be experiencing a turnaround! For more on…